IceCure Medical Ltd (ICCM)

NCM – Real vaqt narxi. Valyuta: USD

0.24

0.00 (0.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.23

-0.01 (-2.21%)

Bozor oldidan: May 13, 2026, 7:43 AM EDT

12.05.2026

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

12.05.2026

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03.

12.05.2026

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance Accelerating adoption of ProSense® driven by several growth catalysts, including FDA clearance, expanding reimbursement framework, media coverage, growing body of clinical data and recommendation of cryoablation for breast cancer in leading clinical guidelines Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, May 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2026 as well as recent commercial and clinical updates.

06.05.2026

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2026 before the Nasdaq Stock Market opens on Tuesday, May 12, 2026.

05.05.2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's meeting American Society of Breast Surgeons (ASBrS) recently recommend cryoablation for low-risk breast cancer in its updated Resource Guide IceCure sponsored a cryoablation symposium led by Key Opinion Leader breast physicians from leading medical institutions including Cleveland Clinic, University of Michigan, West Cancer Center, and the Warren Alpert Medical School of Brown University who shared their thoughts about and their experience using ProSense® Company expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in the first quarter of 2026 compared the same period last year, based on preliminary, unaudited estimates CAESAREA, Israel, May 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation in the American Society of Breast Surgeons ("ASBrS") 2026 Annual Meeting, in Seattle from April 29 to May 3, 2026, where it exhibited ProSense® and sponsored a breakfast symposium titled "Unlocking De-Escalation: Cryoablation for Breast Cancer.

21.04.2026

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates Cryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract Award CAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd.

26.03.2026

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

05.05.2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

21.04.2026

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

26.03.2026

IceCure Medical Ltd (ICCM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

IceCure Medical Ltd (ICCM)

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Videolar

No Data

Press-relizlar

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Videolar

No Data

Press-relizlar

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Search stocks

IceCure Medical Ltd (ICCM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

IceCure Medical Ltd (ICCM)

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Videolar

No Data

Press-relizlar

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Videolar

No Data

Press-relizlar

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement